PlateletBio
United States
- Watertown, Massachusetts
- 04/11/2021
- Series B
- $75,500,000
PlateletBio is the only allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a completely new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a superior cell therapy empowered to tackle previously unmet medical challenges.
- Industry Biotechnology Research
- Website https://www.plateletbio.com/
- LinkedIn https://www.linkedin.com/company/platelet-biogenesis/about/
Related People
Sam RastyFounder
United States -
Greater Boston
Biotech CEO with 25+ years of experience in leadership roles of increasing responsibility spanning global large pharma, mid-cap pharma and small, private biotech. Success in start-up company formation and launch, strategy formulation, fund raising, operations, R&D, manufacturing, corporate development, BD&L and M&A. Strategic and operational leader with product development experience in multiple therapeutic areas and technology platforms spanning small molecules to biologics to more complex gene and cell therapies.
NuCube Energy | $13,000,000 | (Feb 20, 2026)
Vizzia | $35,300,400 | (Feb 20, 2026)
PolyGone Systems Inc | $4,000,000 | (Feb 20, 2026)
Altesa BioSciences, Inc. | $75,000,000 | (Feb 20, 2026)
Eagle Wireless | $30,000,000 | (Feb 20, 2026)
Stacks | $23,000,000 | (Feb 20, 2026)
SPRX | $31,000,000 | (Feb 20, 2026)
Adronite | $5,000,000 | (Feb 20, 2026)
Odynn | $9,500,000 | (Feb 20, 2026)
Ascent(US) | $45,000,000 | (Feb 20, 2026)
Ownwell | $50,000,000 | (Feb 20, 2026)
Badge | $17,100,000 | (Feb 20, 2026)